{"entity":{"type":"insider","cik":"0001350855","url":"/insider/0001350855","json_url":"/insider/0001350855.json","name":"Efficacy Capital, Ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":60,"n_filings":24,"first":"2007-11-02","last":"2011-03-17","span_basis":"filed_date"},"name_variants":[{"name":"Efficacy Capital, Ltd.","source":"filing","n_filings":24,"first_seen":"2007-11-02","last_seen":"2011-03-17"}],"transactions":[{"id":8966258,"accession":"0001140361-11-017510","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-11-017510","line_url":"/filing/0001140361-11-017510#line-2","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3799380.0,"shares_display":"3,799,380","price_per_share":0.61,"price_display":"0.61","price_state":"stated","total_value":2317621.8,"total_display":"2,317,621.80","total_whole":"2,317,622","shares_owned_after":4349432.0,"shares_owned_after_display":"4,349,432","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-03-16","filed_date":"2011-03-17","scope":"insider"},{"id":8966257,"accession":"0001140361-11-017510","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-11-017510","line_url":"/filing/0001140361-11-017510#line-1","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":193234.0,"shares_display":"193,234","price_per_share":0.76,"price_display":"0.76","price_state":"stated","total_value":146857.84,"total_display":"146,857.84","total_whole":"146,858","shares_owned_after":8148812.0,"shares_owned_after_display":"8,148,812","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-03-15","filed_date":"2011-03-17","scope":"insider"},{"id":9072713,"accession":"0001140361-11-010589","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-11-010589","line_url":"/filing/0001140361-11-010589#line-2","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57600.0,"shares_display":"57,600","price_per_share":0.97,"price_display":"0.97","price_state":"stated","total_value":55872.0,"total_display":"55,872.00","total_whole":"55,872","shares_owned_after":8342046.0,"shares_owned_after_display":"8,342,046","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-17","scope":"insider"},{"id":9072712,"accession":"0001140361-11-010589","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-11-010589","line_url":"/filing/0001140361-11-010589#line-1","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":0.95,"price_display":"0.95","price_state":"stated","total_value":6650.0,"total_display":"6,650.00","total_whole":"6,650","shares_owned_after":8399646.0,"shares_owned_after_display":"8,399,646","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-15","filed_date":"2011-02-17","scope":"insider"},{"id":5669718,"accession":"0001140361-09-029903","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":76703.0,"shares_display":"76,703","price_per_share":0.6545,"price_display":"0.65","price_state":"stated","total_value":50202.1135,"total_display":"50,202.11","total_whole":"50,202","shares_owned_after":2552233.0,"shares_owned_after_display":"2,552,233","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-21","filed_date":"2009-12-21","scope":"insider"},{"id":5669717,"accession":"0001140361-09-029903","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":0.676,"price_display":"0.68","price_state":"stated","total_value":20280.0,"total_display":"20,280.00","total_whole":"20,280","shares_owned_after":2628936.0,"shares_owned_after_display":"2,628,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-21","scope":"insider"},{"id":5669716,"accession":"0001140361-09-029903","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50100.0,"shares_display":"50,100","price_per_share":0.703,"price_display":"0.70","price_state":"stated","total_value":35220.3,"total_display":"35,220.30","total_whole":"35,220","shares_owned_after":2658936.0,"shares_owned_after_display":"2,658,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-21","scope":"insider"},{"id":5758296,"accession":"0001140361-09-029245","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":181700.0,"shares_display":"181,700","price_per_share":0.67,"price_display":"0.67","price_state":"stated","total_value":121739.0,"total_display":"121,739.00","total_whole":"121,739","shares_owned_after":2709036.0,"shares_owned_after_display":"2,709,036","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-15","filed_date":"2009-12-15","scope":"insider"},{"id":5758293,"accession":"0001140361-09-029245","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":77900.0,"shares_display":"77,900","price_per_share":0.699,"price_display":"0.70","price_state":"stated","total_value":54452.1,"total_display":"54,452.10","total_whole":"54,452","shares_owned_after":2890736.0,"shares_owned_after_display":"2,890,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-14","filed_date":"2009-12-15","scope":"insider"},{"id":5758288,"accession":"0001140361-09-029245","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":126500.0,"shares_display":"126,500","price_per_share":0.696,"price_display":"0.70","price_state":"stated","total_value":88044.0,"total_display":"88,044.00","total_whole":"88,044","shares_owned_after":2968636.0,"shares_owned_after_display":"2,968,636","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-11","filed_date":"2009-12-15","scope":"insider"},{"id":5588364,"accession":"0001140361-09-027917","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262000.0,"shares_display":"262,000","price_per_share":0.6957,"price_display":"0.70","price_state":"stated","total_value":182273.4,"total_display":"182,273.40","total_whole":"182,273","shares_owned_after":3095136.0,"shares_owned_after_display":"3,095,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-02","filed_date":"2009-12-02","scope":"insider"},{"id":5588363,"accession":"0001140361-09-027917","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131000.0,"shares_display":"131,000","price_per_share":0.7084,"price_display":"0.71","price_state":"stated","total_value":92800.4,"total_display":"92,800.40","total_whole":"92,800","shares_owned_after":3357136.0,"shares_owned_after_display":"3,357,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-01","filed_date":"2009-12-02","scope":"insider"},{"id":5588362,"accession":"0001140361-09-027917","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":148000.0,"shares_display":"148,000","price_per_share":0.7127,"price_display":"0.71","price_state":"stated","total_value":105479.6,"total_display":"105,479.60","total_whole":"105,480","shares_owned_after":3488136.0,"shares_owned_after_display":"3,488,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-30","filed_date":"2009-12-02","scope":"insider"},{"id":5843395,"accession":"0001140361-09-027215","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":227000.0,"shares_display":"227,000","price_per_share":0.7013,"price_display":"0.70","price_state":"stated","total_value":159195.1,"total_display":"159,195.10","total_whole":"159,195","shares_owned_after":3636136.0,"shares_owned_after_display":"3,636,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-23","filed_date":"2009-11-23","scope":"insider"},{"id":5843393,"accession":"0001140361-09-027215","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":215000.0,"shares_display":"215,000","price_per_share":0.7069,"price_display":"0.71","price_state":"stated","total_value":151983.5,"total_display":"151,983.50","total_whole":"151,984","shares_owned_after":3863136.0,"shares_owned_after_display":"3,863,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-20","filed_date":"2009-11-23","scope":"insider"},{"id":5843390,"accession":"0001140361-09-027215","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":214000.0,"shares_display":"214,000","price_per_share":0.7487,"price_display":"0.75","price_state":"stated","total_value":160221.8,"total_display":"160,221.80","total_whole":"160,222","shares_owned_after":4078136.0,"shares_owned_after_display":"4,078,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-19","filed_date":"2009-11-23","scope":"insider"},{"id":3678184,"accession":"0001104659-08-067952","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-067952","line_url":"/filing/0001104659-08-067952#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Master Fund Ltd.; Lappe Mark; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11300.0,"shares_display":"11,300","price_per_share":7.76,"price_display":"7.76","price_state":"stated","total_value":87688.0,"total_display":"87,688.00","total_whole":"87,688","shares_owned_after":4292136.0,"shares_owned_after_display":"4,292,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-31","filed_date":"2008-11-04","scope":"insider"},{"id":3706766,"accession":"0001104659-08-067039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-067039","line_url":"/filing/0001104659-08-067039#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24400.0,"shares_display":"24,400","price_per_share":6.97,"price_display":"6.97","price_state":"stated","total_value":170068.0,"total_display":"170,068.00","total_whole":"170,068","shares_owned_after":4280836.0,"shares_owned_after_display":"4,280,836","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-29","filed_date":"2008-10-30","scope":"insider"},{"id":3706765,"accession":"0001104659-08-067039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-067039","line_url":"/filing/0001104659-08-067039#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9892.0,"shares_display":"9,892","price_per_share":6.87,"price_display":"6.87","price_state":"stated","total_value":67958.04,"total_display":"67,958.04","total_whole":"67,958","shares_owned_after":4256436.0,"shares_owned_after_display":"4,256,436","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-28","filed_date":"2008-10-30","scope":"insider"},{"id":3441216,"accession":"0001104659-08-066016","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-08-066016","line_url":"/filing/0001104659-08-066016#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14825.0,"shares_display":"14,825","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":101551.25,"total_display":"101,551.25","total_whole":"101,551","shares_owned_after":4246544.0,"shares_owned_after_display":"4,246,544","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-27","filed_date":"2008-10-27","scope":"insider"},{"id":3441214,"accession":"0001104659-08-066016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-066016","line_url":"/filing/0001104659-08-066016#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":6.89,"price_display":"6.89","price_state":"stated","total_value":206700.0,"total_display":"206,700.00","total_whole":"206,700","shares_owned_after":4231719.0,"shares_owned_after_display":"4,231,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-24","filed_date":"2008-10-27","scope":"insider"},{"id":3441212,"accession":"0001104659-08-066016","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-066016","line_url":"/filing/0001104659-08-066016#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17309.0,"shares_display":"17,309","price_per_share":6.32,"price_display":"6.32","price_state":"stated","total_value":109392.88,"total_display":"109,392.88","total_whole":"109,393","shares_owned_after":4201719.0,"shares_owned_after_display":"4,201,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-23","filed_date":"2008-10-27","scope":"insider"},{"id":3534535,"accession":"0001104659-08-065013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-065013","line_url":"/filing/0001104659-08-065013#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Lappe Mark; Efficacy Capital, Ltd.; Kayyem Jon Faiz; Efficacy Biotech Fund LTD","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":6.42,"price_display":"6.42","price_state":"stated","total_value":192600.0,"total_display":"192,600.00","total_whole":"192,600","shares_owned_after":4184410.0,"shares_owned_after_display":"4,184,410","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-17","filed_date":"2008-10-21","scope":"insider"},{"id":3136742,"accession":"0001104659-08-064095","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-064095","line_url":"/filing/0001104659-08-064095#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":6.82,"price_display":"6.82","price_state":"stated","total_value":102300.0,"total_display":"102,300.00","total_whole":"102,300","shares_owned_after":4154410.0,"shares_owned_after_display":"4,154,410","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-13","filed_date":"2008-10-14","scope":"insider"},{"id":3136736,"accession":"0001104659-08-064095","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-064095","line_url":"/filing/0001104659-08-064095#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15300.0,"shares_display":"15,300","price_per_share":6.23,"price_display":"6.23","price_state":"stated","total_value":95319.0,"total_display":"95,319.00","total_whole":"95,319","shares_owned_after":4139410.0,"shares_owned_after_display":"4,139,410","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-10","filed_date":"2008-10-14","scope":"insider"},{"id":3965285,"accession":"0001104659-08-062364","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-062364","line_url":"/filing/0001104659-08-062364#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1846154.0,"shares_display":"1,846,154","price_per_share":6.5,"price_display":"6.50","price_state":"stated","total_value":12000001.0,"total_display":"12,000,001.00","total_whole":"12,000,001","shares_owned_after":4124110.0,"shares_owned_after_display":"4,124,110","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-02","filed_date":"2008-10-06","scope":"insider"},{"id":3260645,"accession":"0001104659-08-044049","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-8","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55800.0,"shares_display":"55,800","price_per_share":9.55,"price_display":"9.55","price_state":"stated","total_value":532890.0,"total_display":"532,890.00","total_whole":"532,890","shares_owned_after":2277956.0,"shares_owned_after_display":"2,277,956","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-27","filed_date":"2008-07-03","scope":"insider"},{"id":3260640,"accession":"0001104659-08-044049","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-7","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":9.82,"price_display":"9.82","price_state":"stated","total_value":98200.0,"total_display":"98,200.00","total_whole":"98,200","shares_owned_after":2333756.0,"shares_owned_after_display":"2,333,756","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-26","filed_date":"2008-07-03","scope":"insider"},{"id":3260624,"accession":"0001104659-08-044049","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-6","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":9.58,"price_display":"9.58","price_state":"stated","total_value":574800.0,"total_display":"574,800.00","total_whole":"574,800","shares_owned_after":2343756.0,"shares_owned_after_display":"2,343,756","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-25","filed_date":"2008-07-03","scope":"insider"},{"id":3260619,"accession":"0001104659-08-044049","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-5","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":9.61,"price_display":"9.61","price_state":"stated","total_value":480500.0,"total_display":"480,500.00","total_whole":"480,500","shares_owned_after":2403756.0,"shares_owned_after_display":"2,403,756","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-24","filed_date":"2008-07-03","scope":"insider"},{"id":3260615,"accession":"0001104659-08-044049","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-4","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34000.0,"shares_display":"34,000","price_per_share":8.94,"price_display":"8.94","price_state":"stated","total_value":303960.0,"total_display":"303,960.00","total_whole":"303,960","shares_owned_after":2453756.0,"shares_owned_after_display":"2,453,756","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-20","filed_date":"2008-07-03","scope":"insider"},{"id":3260609,"accession":"0001104659-08-044049","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10600.0,"shares_display":"10,600","price_per_share":8.9,"price_display":"8.90","price_state":"stated","total_value":94340.0,"total_display":"94,340.00","total_whole":"94,340","shares_owned_after":2487756.0,"shares_owned_after_display":"2,487,756","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-18","filed_date":"2008-07-03","scope":"insider"},{"id":3260603,"accession":"0001104659-08-044049","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55357.0,"shares_display":"55,357","price_per_share":8.54,"price_display":"8.54","price_state":"stated","total_value":472748.78,"total_display":"472,748.78","total_whole":"472,749","shares_owned_after":2498356.0,"shares_owned_after_display":"2,498,356","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-17","filed_date":"2008-07-03","scope":"insider"},{"id":3260594,"accession":"0001104659-08-044049","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-044049","line_url":"/filing/0001104659-08-044049#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26300.0,"shares_display":"26,300","price_per_share":8.59,"price_display":"8.59","price_state":"stated","total_value":225917.0,"total_display":"225,917.00","total_whole":"225,917","shares_owned_after":2553713.0,"shares_owned_after_display":"2,553,713","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-14","filed_date":"2008-07-03","scope":"insider"},{"id":2988011,"accession":"0001104659-08-017478","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-017478","line_url":"/filing/0001104659-08-017478#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":425000.0,"total_display":"425,000.00","total_whole":"425,000","shares_owned_after":2580013.0,"shares_owned_after_display":"2,580,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-12","filed_date":"2008-03-13","scope":"insider"},{"id":4013235,"accession":"0001104659-08-016855","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-016855","line_url":"/filing/0001104659-08-016855#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Fund LTD; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":8.46,"price_display":"8.46","price_state":"stated","total_value":338400.0,"total_display":"338,400.00","total_whole":"338,400","shares_owned_after":2530013.0,"shares_owned_after_display":"2,530,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-10","filed_date":"2008-03-11","scope":"insider"},{"id":4013232,"accession":"0001104659-08-016855","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-016855","line_url":"/filing/0001104659-08-016855#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Fund LTD; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34500.0,"shares_display":"34,500","price_per_share":8.63,"price_display":"8.63","price_state":"stated","total_value":297735.0,"total_display":"297,735.00","total_whole":"297,735","shares_owned_after":2530013.0,"shares_owned_after_display":"2,530,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-03-07","filed_date":"2008-03-11","scope":"insider"},{"id":4124565,"accession":"0001104659-08-014848","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-014848","line_url":"/filing/0001104659-08-014848#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":8.27,"price_display":"8.27","price_state":"stated","total_value":248100.0,"total_display":"248,100.00","total_whole":"248,100","shares_owned_after":2455513.0,"shares_owned_after_display":"2,455,513","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-02-29","filed_date":"2008-03-03","scope":"insider"},{"id":4124560,"accession":"0001104659-08-014848","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-014848","line_url":"/filing/0001104659-08-014848#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":8.35,"price_display":"8.35","price_state":"stated","total_value":167000.0,"total_display":"167,000.00","total_whole":"167,000","shares_owned_after":2425513.0,"shares_owned_after_display":"2,425,513","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-02-28","filed_date":"2008-03-03","scope":"insider"},{"id":3925858,"accession":"0001104659-08-001299","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-001299","line_url":"/filing/0001104659-08-001299#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Lappe Mark","owner_display_name":"Kayyem Jon Faiz","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19500.0,"shares_display":"19,500","price_per_share":9.08,"price_display":"9.08","price_state":"stated","total_value":177060.0,"total_display":"177,060.00","total_whole":"177,060","shares_owned_after":2405513.0,"shares_owned_after_display":"2,405,513","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-01-07","filed_date":"2008-01-08","scope":"insider"},{"id":3925857,"accession":"0001104659-08-001299","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-001299","line_url":"/filing/0001104659-08-001299#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Lappe Mark","owner_display_name":"Kayyem Jon Faiz","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":8.96,"price_display":"8.96","price_state":"stated","total_value":134400.0,"total_display":"134,400.00","total_whole":"134,400","shares_owned_after":2386913.0,"shares_owned_after_display":"2,386,913","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-01-04","filed_date":"2008-01-08","scope":"insider"},{"id":2657838,"accession":"0001104659-08-000255","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-000255","line_url":"/filing/0001104659-08-000255#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":54100.0,"shares_display":"54,100","price_per_share":9.43,"price_display":"9.43","price_state":"stated","total_value":510163.0,"total_display":"510,163.00","total_whole":"510,163","shares_owned_after":2371013.0,"shares_owned_after_display":"2,371,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-31","filed_date":"2008-01-02","scope":"insider"},{"id":2657831,"accession":"0001104659-08-000255","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-000255","line_url":"/filing/0001104659-08-000255#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":70000.0,"shares_display":"70,000","price_per_share":9.32,"price_display":"9.32","price_state":"stated","total_value":652400.0,"total_display":"652,400.00","total_whole":"652,400","shares_owned_after":2316913.0,"shares_owned_after_display":"2,316,913","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-28","filed_date":"2008-01-02","scope":"insider"},{"id":7128616,"accession":"0001104659-07-090718","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-07-090718","line_url":"/filing/0001104659-07-090718#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.","owner_display_name":"Kayyem Jon Faiz","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":9.38,"price_display":"9.38","price_state":"stated","total_value":375200.0,"total_display":"375,200.00","total_whole":"375,200","shares_owned_after":2246913.0,"shares_owned_after_display":"2,246,913","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-21","filed_date":"2007-12-21","scope":"insider"},{"id":7128615,"accession":"0001104659-07-090718","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-07-090718","line_url":"/filing/0001104659-07-090718#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Kayyem Jon Faiz; Efficacy Biotech Master Fund Ltd.; Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.","owner_display_name":"Kayyem Jon Faiz","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":9.49,"price_display":"9.49","price_state":"stated","total_value":569400.0,"total_display":"569,400.00","total_whole":"569,400","shares_owned_after":2206913.0,"shares_owned_after_display":"2,206,913","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-20","filed_date":"2007-12-21","scope":"insider"},{"id":7693767,"accession":"0001104659-07-090170","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-07-090170","line_url":"/filing/0001104659-07-090170#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":43500.0,"shares_display":"43,500","price_per_share":9.84,"price_display":"9.84","price_state":"stated","total_value":428040.0,"total_display":"428,040.00","total_whole":"428,040","shares_owned_after":null,"shares_owned_after_display":null,"ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-19","filed_date":"2007-12-20","scope":"insider"},{"id":7693765,"accession":"0001104659-07-090170","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-07-090170","line_url":"/filing/0001104659-07-090170#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":42100.0,"shares_display":"42,100","price_per_share":9.79,"price_display":"9.79","price_state":"stated","total_value":412159.0,"total_display":"412,159.00","total_whole":"412,159","shares_owned_after":null,"shares_owned_after_display":null,"ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-18","filed_date":"2007-12-20","scope":"insider"},{"id":7732793,"accession":"0001104659-07-089559","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-07-089559","line_url":"/filing/0001104659-07-089559#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":120000.0,"shares_display":"120,000","price_per_share":9.78,"price_display":"9.78","price_state":"stated","total_value":1173600.0,"total_display":"1,173,600.00","total_whole":"1,173,600","shares_owned_after":2061313.0,"shares_owned_after_display":"2,061,313","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-14","filed_date":"2007-12-18","scope":"insider"},{"id":7732791,"accession":"0001104659-07-089559","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-07-089559","line_url":"/filing/0001104659-07-089559#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40100.0,"shares_display":"40,100","price_per_share":8.7,"price_display":"8.70","price_state":"stated","total_value":348870.0,"total_display":"348,870.00","total_whole":"348,870","shares_owned_after":1941313.0,"shares_owned_after_display":"1,941,313","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-13","filed_date":"2007-12-18","scope":"insider"},{"id":7072885,"accession":"0001104659-07-087805","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-07-087805","line_url":"/filing/0001104659-07-087805#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Kayyem Jon Faiz; Lappe Mark; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":7.96,"price_display":"7.96","price_state":"stated","total_value":477600.0,"total_display":"477,600.00","total_whole":"477,600","shares_owned_after":1901213.0,"shares_owned_after_display":"1,901,213","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-12-06","filed_date":"2007-12-07","scope":"insider"}],"collapsed":true,"next_cursor":"2007-12-06|7072885","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001261734","name":"AEOLUS PHARMACEUTICALS, INC.","url":"/issuer/0001261734","role":"Ten percent owner","n_filings":2,"first_seen":"2011-02-17","last_seen":"2011-03-17"},{"type":"issuer","type_label":"ISSUER","cik":"0000897075","name":"REPROS THERAPEUTICS INC.","url":"/issuer/0000897075","role":"Ten percent owner","n_filings":22,"first_seen":"2007-11-02","last_seen":"2009-12-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001350855","retrieved_at":"2026-08-22T08:29:24+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}